Medical AI firm VUNO has obtained the South Korean Ministry of Meals and Drug Security’s clearance for its private ECG system.
Referred to as Hativ Professional, the transportable medical system merely measures a consumer’s coronary heart price and sends this information by means of a related cell phone app.
WHY IT MATTERS
VUNO has been providing a spread of medical AI options for docs and well being services. Following this newest authorities certification, VUNO can lastly transfer in direction of providing AI medical gadgets to shoppers.
With the MFDS clearance, the corporate plans to quickly launch its built-in well being administration model Hativ, that includes AI-powered residence medical gadgets that assist shoppers’ every day well being administration and early analysis of continual ailments.
VUNO continues to strengthen its medical AI enterprise primarily based on ECG information, which the corporate claims have “excessive potential as a biomarker for varied cardiovascular ailments”. In South Korea, CVDs are the second main reason for dying after most cancers with circumstances rising every year on account of an ageing inhabitants.
“By way of our ECG data-based medical AI undertaking, we’ll do our greatest to cut back mortality from heart problems and contribute to preventive therapy – the longer term route of medical care,” stated VUNO CEO Lee Ye Ha.
Sooner or later, VUNO plans to launch extra residence AI medical gadgets for detecting main coronary heart ailments.
THE LARGER TREND
In current months, VUNO has been gathering a number of regulatory approvals to market its AI medical options in South Korea and the remainder of Asia-Pacific.
In March, VUNO secured the South Korean authorities’s approval for VUNO Med LungQuant, an AI-based lung CT quantification resolution for the exact analysis and screening of lung ailments. Final yr, it additionally obtained an MFDS clearance for VUNO Med DeepCARS, a medical system that makes use of AI to analyse an individual’s danger for cardiac arrest.
Within the first half of the yr, the corporate additionally obtained market approvals in Thailand, Saudi Arabia, and Malaysia for its different VUNO Med choices.
